Actively Recruiting
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Led by TG Therapeutics, Inc. · Updated on 2026-04-03
360
Participants Needed
42
Research Sites
181 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
CONDITIONS
Official Title
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Relapsing Multiple Sclerosis according to 2017 Revised McDonald criteria
- Expanded Disability Status Scale (EDSS) score of 5.5 or less at screening
- Neurologically stable for more than 30 days prior to screening and Day 1
- Female participants of childbearing potential must agree to use highly effective contraception from consent through 6 months after last dose of ublituximab
You will not qualify if you...
- Primary-progressive Multiple Sclerosis (PPMS) or inactive Secondary Progressive Multiple Sclerosis (SPMS)
- Active chronic immune system disease other than MS or immunodeficiency syndrome
- Significant bone marrow impairment or significant leukopenia or thrombocytopenia
- Previous treatment with anti-CD20 therapy at any time
- Use of any approved MS therapy within 5 half-lives prior to screening
- Other inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 42 locations
1
TG Therapeutics Investigational Trial Site
Banja Luka, Bosnia and Herzegovina, 78000
Actively Recruiting
2
TG Therapeutics Investigational Trial Site
Bihać, Bosnia and Herzegovina, 77000
Actively Recruiting
3
TG Therapeutics Investigational Trial Site
Mostar, Bosnia and Herzegovina, 71000
Actively Recruiting
4
TG Therapeutics Investigational Trial Site
Saravejo, Bosnia and Herzegovina, 71000
Actively Recruiting
5
TG Therapeutics Investigational Trial Site
Pleven, Bulgaria, 5800
Actively Recruiting
6
TG Therapeutics Investigational Trial Site
Plovdiv, Bulgaria, 4000
Actively Recruiting
7
TG Therapeutics Investigational Trial Site
Sofia, Bulgaria, 1000
Actively Recruiting
8
TG Therapeutics Investigational Trial Site
Veliko Tarnovo, Bulgaria, 5000
Actively Recruiting
9
TG Therapeutics Investigational Trial Site
Varaždin, Croatia, 42000
Actively Recruiting
10
TG Therapeutics Investigational Trial Site
Zagreb, Croatia, 10000
Actively Recruiting
11
TG Therapeutics Investigational Trial Site
Brno, Czechia, 65691
Actively Recruiting
12
TG Therapeutics Investigational Trial Site
Hradec Králové, Czechia, 50005
Actively Recruiting
13
TG Therapeutics Investigational Trial Site
Jihlava, Czechia, 58601
Actively Recruiting
14
TG Therapeutics Investigational Trial Site
Ostrava, Czechia, 70300
Actively Recruiting
15
TG Therapeutics Investigational Trial Site
Pardubice, Czechia, 53002
Actively Recruiting
16
TG Therapeutics Investigational Trial Site
Zlín, Czechia, 76275
Actively Recruiting
17
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0112
Actively Recruiting
18
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0114
Actively Recruiting
19
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0159
Actively Recruiting
20
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0172
Actively Recruiting
21
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0178
Actively Recruiting
22
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0179
Actively Recruiting
23
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 0180
Actively Recruiting
24
TG Therapeutics Investigational Trial Site
Tbilisi, Georgia, 3700
Actively Recruiting
25
TG Therapeutics Investigational Trial Site
Budapest, Hungary, H-1033
Actively Recruiting
26
TG Therapeutics Investigational Trial Site
Budapest, Hungary, H-1145
Actively Recruiting
27
TG Therapeutics Investigational Trial Site
Kaposvár, Hungary, H-7400
Actively Recruiting
28
TG Therapeutics Investigational Trial Site
Kistarsca, Hungary, H-2143
Actively Recruiting
29
TG Therapeutics Investigational Trial Site
Pécs, Hungary, H-7623
Actively Recruiting
30
TG Therapeutics Investigational Trial Site
Shtip, North Macedonia, 7240
Actively Recruiting
31
TG Therapeutics Investigational Trial Site
Skopje, North Macedonia, 1000
Actively Recruiting
32
TG Therapeutics Investigational Trial Site
Cherkasy, Ukraine, 14029
Actively Recruiting
33
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, Ukraine, 76000
Actively Recruiting
34
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, Ukraine, 76018
Actively Recruiting
35
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, Ukraine, 76493
Actively Recruiting
36
TG Therapeutics Investigational Trial Site
Kyiv, Ukraine, 03037
Actively Recruiting
37
TG Therapeutics Investigational Trial Site
Kyiv, Ukraine, 03115
Actively Recruiting
38
TG Therapeutics Investigational Trial Site
Lviv, Ukraine, 79000
Actively Recruiting
39
TG Therapeutics Investigational Trial Site
Lviv, Ukraine, 79010
Actively Recruiting
40
TG Therapeutics Investigational Trial Site
Ternopil, Ukraine, 46027
Actively Recruiting
41
TG Therapeutics Investigational Trial Site
Vinnytsia, Ukraine, 21002
Actively Recruiting
42
TG Therapeutics Investigational Trial Site
Vinnytsia, Ukraine, 21009
Actively Recruiting
Research Team
T
TG Therapeutics Clinical Support Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here